Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Neuropathix Inc (NPTX)

Neuropathix Inc (NPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS ACCESS Newswire - Wed May 25, 2022

The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019 ACCESS Newswire - Wed Apr 13, 2022

Published Preclinical Data Shows KLS-13019 More Effective Than Cannabidiol (CBD) in Prevention, Reversal of Chemotherapy-Induced Peripheral Neuropathy (CIPN) DOYLESTOWN, PA / ACCESSWIRE / April 13, 2022...

NPTX : 0.0003 (unch)
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding ACCESS Newswire - Wed Apr 6, 2022

DOYLESTOWN, PA / ACCESSWIRE / April 6, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CEO...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board ACCESS Newswire - Tue Jan 25, 2022

DOYLESTOWN, PA / ACCESSWIRE / January 25, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it has...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds ACCESS Newswire - Tue Jan 18, 2022

DOYLESTOWN, PA / ACCESSWIRE / January 18, 2022 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that the...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019 ACCESS Newswire - Wed Nov 17, 2021

DOYLESTOWN, PA / ACCESSWIRE / November 17, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible life sciences company focused on the research and development of...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS) ACCESS Newswire - Tue Sep 28, 2021

Pharmaceutical Assets Include Company's Non-Opioid Anti-inflammatory Compound KLS-13019 to Treat Chemotherapy Induced Peripheral Neuropathy (CIPN) Company's Strategy is to Utilize the Phase 2 Study Grant...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets ACCESS Newswire - Tue Aug 24, 2021

Cosmeceutical Assets Include Company's Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company's Strategy is to Enable Dermique to Focus...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board ACCESS Newswire - Thu Aug 12, 2021

DOYLESTOWN, PA / ACCESSWIRE / August 12, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announces today that it has...

NPTX : 0.0003 (unch)
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders ACCESS Newswire - Tue Jul 20, 2021

DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication...

NPTX : 0.0003 (unch)

Barchart Exclusives

Boeing Jumps on New Pentagon Deal. Should You Buy BA Stock Here? Barchart - 1 hour ago
Boeing stock extended gains on a new landmark agreement with the Pentagon. Wells Fargo recommends buying BA shares into strength. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.